KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Capital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Alnylam Pharmaceuticals (ALNY) Amortization of Deferred Charges (2019 - 2024)

Historic Amortization of Deferred Charges for Alnylam Pharmaceuticals (ALNY) over the last 6 years, with Q3 2024 value amounting to $13.1 million.

  • Alnylam Pharmaceuticals' Amortization of Deferred Charges rose 2794.98% to $13.1 million in Q3 2024 from the same period last year, while for Sep 2024 it was $45.2 million, marking a year-over-year increase of 498.14%. This contributed to the annual value of $43.0 million for FY2023, which is 461.27% up from last year.
  • According to the latest figures from Q3 2024, Alnylam Pharmaceuticals' Amortization of Deferred Charges is $13.1 million, which was up 2794.98% from $9.7 million recorded in Q2 2024.
  • Over the past 5 years, Alnylam Pharmaceuticals' Amortization of Deferred Charges peaked at $13.1 million during Q3 2024, and registered a low of $9.4 million during Q1 2020.
  • Over the past 5 years, Alnylam Pharmaceuticals' median Amortization of Deferred Charges value was $10.3 million (recorded in 2023), while the average stood at $10.6 million.
  • In the last 5 years, Alnylam Pharmaceuticals' Amortization of Deferred Charges crashed by 1210.43% in 2022 and then surged by 2794.98% in 2024.
  • Quarter analysis of 5 years shows Alnylam Pharmaceuticals' Amortization of Deferred Charges stood at $10.5 million in 2020, then decreased by 3.98% to $10.1 million in 2021, then grew by 4.94% to $10.6 million in 2022, then fell by 0.78% to $10.5 million in 2023, then grew by 24.45% to $13.1 million in 2024.
  • Its Amortization of Deferred Charges was $13.1 million in Q3 2024, compared to $9.7 million in Q2 2024 and $12.0 million in Q1 2024.